3
Announcements
Trials
Browse
Landscape
Phase
Phase NA
1
Status
Withdrawn
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Dermatologic
1
Conditions
Carcinoma, Basal Cell
3
Pancreatic Neoplasms
2
Urologic Neoplasms
1
Urinary Bladder Neoplasms
1
Telangiectasis
1
Skin Neoplasms
1
Rosacea
1
Prostatic Neoplasms
1
Precancerous Conditions
1
Port-Wine Stain
1
Pancreatic Intraductal Neoplasms
1
Non-melanoma Skin Cancer
1
Nevus, Pigmented
1
Nasopharyngeal Neoplasms
1
Mixed Tumor, Malignant
1
Melanoma
1
Lung Neoplasms
1
Keratosis, Seborrheic
1
Keratosis
1
Hemangioma
1
Glioma
1
Carcinoma, Transitional Cell
1
Carcinoma
1
Barrett Esophagus
1
Interventions
Cisplatin
55
Carboplatin
49
pembrolizumab
42
Paclitaxel
42
Gemcitabine
28
Pemetrexed
23
Radiotherapy
21
Magnetic Resonance Spectroscopy
20
Radiotherapy, Intensity-Modulated
18
Docetaxel
17
Cetuximab
17
Specimen Handling
16
Nivolumab
16
Fluorouracil
16
Cyclophosphamide
14
durvalumab
13
Bevacizumab
12
Radiation
11
Sorafenib
10
Platinum
10
130-nm albumin-bound paclitaxel
10
1,2-diaminocyclohexaneplatinum II citrate
10
osimertinib
9
Sunitinib
8
Oxaliplatin
8
Irinotecan
8
Ipilimumab
8
Everolimus
8
Drug Therapy
8
Capecitabine
8
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Interventional
×
Carcinoma
×
Tomography, Optical Coherence
×
Clear all
NCT02851693
2019-04-04
OCTSKIN
Centre Hospitalier Universitaire de Saint Etienne
Phase NA
Withdrawn